Background: Due to high IgE recognition frequency and high allergenic activity, Der
them the major allergens, Der p 1, Der p 2 and Der p 23 and a group of mid-tier allergens including Der p 5 and Der p 21 which in some population are recognized by more than 50% of HDM-allergic patients. [5] [6] [7] Groups 5 and 21 house dust mite (HDM) allergens were identified in Dermatophagoides pteronyssinus, Dermatophagoides farinae and Blomia tropicalis and were shown in several studies to be important allergens with high allergenic activity in terms of inducing effector cell activation and skin inflammation. [8] [9] [10] [11] [12] A recently published study investigating the prevalence of IgE recognition and the development of the evolution of IgE sensitizations to HDM allergens in a large birth cohort in Germany highlighted the importance of Der p 5 and Der p 21 because approximately 20% to 30% of the participants were sensitized against these allergens. 13 In another study performed in HDM-allergic children suffering only from rhinitis or rhinitis and asthma, sensitization to Der p 5 and Der p 21 occurred more frequently in the children who also suffered from asthma and asthmatic children more frequently recognized several different HDM allergens including Der p 5 and Der p 21 compared to children without asthma. 14 Der p 5 and Der p 21 are therefore clinically important allergens, but it has been found that these two allergens are poorly represented in currently manufactured allergen extracts. 15 It is therefore difficult to develop HDM allergy vaccines based on natural allergen extracts which protect HDM-allergic patients who are sensitized to these allergens. One possibility to overcome the limitations of natural allergen extracts for HDM-specific immunotherapy is therefore to develop molecular vaccines which are based on recombinant allergens, allergen derivatives or allergenderived peptides. 16 Several new forms of allergy vaccines have been successfully evaluated in clinical trials which are based on defined molecular components. 17, 18 The construction of these vaccines depends heavily on the definition of the clinically relevant allergens of a given allergen source and the knowledge of IgE and T-cell epitopes of the key allergens. In fact, the three-dimensional structure of Der p 5 has been revealed and shows a three-helical bundle that can polymerize to create a hydrophobic cavity which could possibly be a ligand-binding site. 19 Also Der p 21 seems to have a similar three-dimensional structure (ie, forms a three-helical bundle protein)
but shows no IgE cross-reactivity with Der p 5. 10 Here, we performed a detailed analysis of the IgE epitopes of Der p 5 and Der p 21 to break the ground for a broadly protective HDM allergy vaccine.
| MATERIALS AND METHODS

| Synthetic peptides, rDer p 5 and rDer p 21, molecular modelling
Peptides were synthesized using Applied Biosystems peptide synthesizer Model 433A (Foster City, CA, USA) and purified by HPLC as described previously. 20 Identity of each of the synthetic peptides was confirmed by matrix-assisted laser desorption ionizationtime of flight (MALDI-TOF) analysis (Bruker, Billerica, MA, USA).
For the purpose of rabbit immunization, each of the peptides was coupled to keyhole limpet haemocyanin (KLH) (MW 4.5 9 10 5 À1. 3 9 10 7 Daltons; Pierce, ThermoFisher Scientific, Waltham, MA, USA) and purified using a conjugation kit according to manufacturer's instructions (Pierce, ThermoFisher Scientific). Table S1 ). Figure 1B shows the localization of the four peptides on the three-dimensional structure of Der p 5. In the given view, P1 and P2 appear on the front side, whereas P3 and P4 are located on the backside of the modelled structure (Figure 1B) . The coverage of surface by the individual Der p 5 peptides was as follows: peptide 1: 34%, peptide 2: 28%, peptide 3: 29% and peptide 4: 31%.
Similar as for Der p 5, we were able to cover the sequence of Der p 21 with four overlapping peptides (P1-P4) with a length from 29 to 36 amino acids ( Figure 1C , Table S1 ). When the Der p 21-derived peptides 1-4 were projected on the 3D model of the Der p 21, P1 and P3 appeared to define a surface patch close to the N-terminus, while P2 and P4 define a patch on the opposite side of the molecule where the C-terminus is located ( Figure 1D ). To further reduce the IgE reactivity of the peptides, we shortened the length of P1 and P4 for 5 amino acids at their C-(P1-1, P4-1) or N-termini (P1-2, P4-2) ( Figure 1A , Table S1 ). Shortening of the peptides at their C termini did not abolish patients IgE binding to P1-1 and P4-1 completely but when the peptides were shortened at the N-termini, IgE binding to P1-2 and P4-2 was completely abolished ( Figure 2B , patients 3-49).
IgE reactivity of the four Der p 21-derived peptides was compared with that of complete Der p 21 in 25 Der p 21-sensitized patients by dot-blot assay ( Figure 2C ). P4 showed no IgE reactivity, P1 showed weak, barely detectable IgE reactivity with two sera, P2 reacted weakly with one serum, and P3 showed residual IgE reactivity with 10 of the patients' sera ( Figure 2C ). Again no reactivity was observed with serum from a nonallergic subject, and the control protein BSA also showed no IgE reactivity ( Figure 2C ). When alum was used as an adjuvant for immunization of the rabbits, the highest mean inhibition was obtained by anti-P4 serum (ie, 42%) followed by anti-P1 with a mean inhibition of 35% (Table 1) . Somewhat lower inhibitions were obtained by anti-P3 and anti-P2 (31% and 23%). Combinations of anti-P1 and anti-P2
antibodies as well as of anti-P3 and anti-P4 antibodies did not give relevant increases in IgE inhibition (data not shown). However, when the mix of anti-P1 and anti-P4 antibodies was tested, the mean inhibition could be increased to 60% which was almost in the range of the inhibition obtained with antibodies raised against the complete Der p 5 allergen (79% mean inhibition).
With antisera induced by immunization with CFA stronger inhibitions were obtained because the titres of the antisera were higher than those of the antisera obtained with alum ( Figure S1 , S2, S3) ( The percentages of inhibition of patients' IgE binding to Der p 5 after preincubation with the individual antipeptide antibodies (anti-P1, anti-P2, anti-P3 or anti-P4), mix of anti-P1+P4 or with anti-Der p 5 antibodies obtained vs inhibition with pre-immune sera are shown.
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antibodies was also the highest among the peptide antisera (mean inhibition of 83%) which was comparable with the inhibition obtained with rabbit antibodies raised by immunization with the complete Der p 5 allergen (mean inhibition 81%) ( Table 1) . Antibodies raised against P3 which overlaps for 17 amino acids with P4 also strongly inhibited IgE binding to Der p 5 (mean inhibition 69%).
The mean inhibition with anti-P1 was 53%, and the lowest mean inhibition was obtained for P2-specific antibodies (37%). These results indicate that major IgE-binding epitopes are present on the N-terminus and C-terminus of Der p 5 in the portions containing P1
and P4.
A further refinement of the IgE-binding sites was obtained with
IgE inhibition experiments using antibodies raised against shortened versions of P1 and P4 (ie, anti P1-2 and anti-P4-2 antisera). Table S2 shows that, regardless whether CFA or alum was used as adjuvant, a combination of antisera against P1-2 and P4-2 inhibited IgE binding to Der p 5 as well as antibodies raised against complete Der p 5.
We then mapped Der p 21 IgE epitopes using anti-Der p 21
peptide antibodies ( Figure 3A ). In the folded allergens, the portions defined by these peptides assemble conformational epitope-containing areas on Der p 5 ( Figure 3B ) and Der p 21 ( Figure 3C ). 
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inhibition studies. 10 In fact, we used rabbit anti-allergen and antipeptide antisera to inhibit IgE binding of patients who had IgE antibodies to both allergens (ie, Der p 5 and Der p 21) (n = 5). For these sera, a very limited IgE cross-reactivity could be found (Table 3 (Table 3 ). Second and most important, our study has mapped the major IgE epitope-containing areas of Der p 5 and Der p 21 and we could identify nonallergenic peptides from these areas which can be used for the construction of allergy vaccines based on carrier-bound B cell epitopes. 18, 29 A vaccine based on nonallergenic B cell epitope-derived peptides of the four major timothy grass pollen allergens has in fact been described 30 and was shown to be clinically effective in immunotherapy trials in grass pollen-allergic patients. 31, 32, 33 Our work therefore will be important for the rational engineering of a recombinant vaccine for the treatment of HDM allergy.
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